Replies to post #74603 on Cytodyn Inc (CYDY)

[BioInvestor4]

I agree with you that we currently do not have a seat at the table. I’m well aware of of the politics and pharma’s control of the FDA. Totally understand and agree.

But I will have to disagree with the point that we cannot get a seat at the table (even if it’s forced or not welcomed).

Results is what will do that. Not anecdotal results, not emergency IND patients... only double blinded trial results...which are due around the end of the month.

If the results are the same as Gileads or slightly better, we get ignored.

If the results are a big step above Gileads, thr FDA has no choice. The news will be everywhere and the pressure to intense as this virus continues to be unrelenting.

That, in my option, is our ticket to the dance...

[Blane]

I respect your view point, Grip. But are all companies “not welcome at the table”, or is it just Nader for some reason? And I for one don’t think it should be approved “just because”. So then, What is it?

I’m not saying Nader might not have red tape. But I don’t personally believe that every other conspiracy theory, but pro and con, about Nader and Cytodyn is false, EXCEPT for that one. Is it possible that a buyout may be the only way to get the drug to patients? Maybe. But I think those chances were better before Covid. I think Covid truly has the potential to get Leronlimab approved much quicker than even Anader thought possible. Which is why I think they dropped everything practically to pursue it.

Just my thoughts. For what they’re worth.

Cues that don’t seem right. Kinda of like approving an antiviral that doesn’t do what an antiviral is supposed to do, and a change in end point measurement. Frustrating indeed.